PADMA Inc. – Ancient Tibetan Recipes and Swiss Quality. Tibetan medicine products since 1969

PADMA products are unique herbal blends of knowledge and experience carried over centuries of Tibetan medicine and manufactured to the highest Swiss quality standards since 1969. ‘

PADMA combines the ancient science of Tibetan wisdom with modern science, carefully selected raw materials and Swiss quality. Many PADMA products, such as PADMA Basic for blood supply disorders and atherosclerosis, PADMA Digestin for digestive disorders, and PADMA Nervotonin for nervous system and sleep problems, have proven themselves over the years in Estonia, other European countries, and America.

PRODUCTION AND QUALITY

Padma Inc. manufactures medicines and supplements in accordance with the International Standard for Good Manufacturing Practice (GMP) for Medicines. The company undergoes regular official inspections in Switzerland.

PADMA herbal mixtures consist of carefully blended and comminuted herbal components. The company refrains from using additives such as preservatives, flavorings, dyes. It also follows the Tibetan tradition of using only natural and natural ingredients in herbs. the raw materials used meet the very strict official quality requirements applied to each individual plant. Traces of pesticides, heavy metals or molds in plants immediately preclude their use in production. In addition to chemical analysis methods,

PADMA quality specialists also use their own taste and smell. The human sensory organs act as very sensitive tools that complement the chemical test methods in a significant way.

 

RESEARCH

In recent decades, the requirements for registration of the production of medicines and supplements have steadily increased. The purpose of such prescriptions is to ensure the quality, safety and efficacy of health products. The primary goal of PADMA is to make Tibetan pharmacological products available to Western patients within our modern regulatory framework.

Numerous experimental studies and clinical trials have been conducted on PADMA herbal formulations to describe the mechanisms of action of the products and to prove their efficacy. Scientist are currently researching PADMA products at universities and clinics in Switzerland, Austria, Germany, Denmark, Israel and other countries.

Research results are available in the following areas: Recurrent respiratory tract infections Chronic hepatitis B Chronic arthritis Gastrointestinal problems, constipation, flatulence, irritable bowel syndrome Atherosclerosis of the lower limbs. Peripheral arterial disease – PAD or claudication (the main mechanism of arterial atherosclerosis and related atherothrombosis)

TEE LÄÄNDE

Padma Inc looja, Karl Lutz, osales 1954. aastal Tiibeti traditsioonilise meditsiini loengul ZĂŒrichis.Ta vaimustus loengul Ă”pitust nii, et otsustas kaevuda veelgi enam iidse meditsiinisĂŒsteemi kogemustesse ja filosoofiasse. Olles Ă”ppinud Tiibeti meditsiini mitu aastat elu Karl Lutzi kokku Dr. Peter Padmajeviga, kes omakorda oli Dr. Sul Tim Badma vennapoeg. Dr. Badma oli kuulus Tiibeti arst, kel Ă”nnestus peatada tol ajal Siberit laastanud tĂŒĂŒfuse epideemia. Tema edust sai ka kuulda Vene Tsaar. Viimane kutsus Dr. Badma Sankt Peterburgi, kus ta avas esimese Tiibeti apteegi lÀÀnemaailmas.
Umbes 1960. aastal usaldas Dr. Peter Padmajev oma kuulsa onu retseptid Karl Lutzi hoolde. Saadud materjalide alusel lĂ”i Karl Lutz Tiibeti retseptide uurimisgrupi ZĂŒrichis. Teadlased kĂŒmnest erinevast riigist uurisid neid ĂŒlestĂ€hendusi, mille alusel valmis nimekiri nĂ€idustuste kohta millal ja kuidas kĂ”nealuseid traditsioonilisi taimesegusid kasutada. Nimekiri nĂ€idustuste kohta jagati koos vastvalminud taimsete tablettidega arstidele ĂŒle Ć veitsi.
Martin Saxeril on valminud suurepĂ€rane dokumentaalfilm Tiibeti meditsiini tulekust lÀÀnde pealkirjaga “Journeys with Tibetan Medicine.”

PADMA INC ASUTAMINE

Innustatuna Ć veitsi arstidelt saadud positiivsest tagasisidest asutas Karl Lutz 1969. aastal Padma Inc. ettevĂ”tte, mis hakkas kaasaegsete meetoditega tootma Tiibeti retseptide alusel valmistatud taimseid tablette. 1970. aastal andis Ć veitsi tolleaegne ravimiamet “Swissmedic” oma heakskiidu taimsele segule Padma Lax (nr 179). Seitse aastat hiljem sai heakskiidu jĂ€rgmine toode, Padma 28.
1994. aastal otsustas Karl Lutz minna pensionile ja andis Padma Inc juhtimise ĂŒle oma lĂ€hedasele kaastöötajale Dr. Herbert Shwablile, Austria bio fĂŒĂŒsikule, kes juhib ettevĂ”tet tĂ€nase pĂ€evani.
Koostöö Padma ja Tiibeti arstide ning institutsioonide vahel on sellest ajast jĂ€rjest tihenenud. 1999. aastal kolis firma ZĂŒrichi lĂ€hedale Schwerzenbachi. TĂ€napĂ€eval annab ettevĂ”te tööd ligi viiekĂŒmnele inimesele.